EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor

Claire E Wainwright, Teja Thorat, Sarah Conner, Bradley S Quon, Jamie Duckers, Yiyue Lou, Chen Mo, Yuqing Xue, Ling Zhu, Lisa McGarry

Journal of Cystic Fibrosis · 2026

DOI: 10.1016/j.jcf.2025.11.014 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Cystic Fibrosis, 2026. Verfasst von Claire E Wainwright und 9 weiteren Autor:innen. Beteiligte Einrichtung: Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia. Electronic address: Wainwright@health.qld.gov.au. Hauptthemen laut MEDLINE: Cystic Fibrosis, Quality of Life, Benzodioxoles, Indoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vertex Pharmaceuticals Incorporated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) was shown to provide greater restoration of cystic fibrosis transmembrane conductance regulator (CFTR) function than prior CFTR modulators in people with cystic fibrosis (CF) aged ≥6 years. Here, we assessed the impact of VNZ/TEZ/D-IVA on health-related quality of life (HRQoL) in children, adolescents, and adults with CF. METHODS: Post-hoc analyses were conducted using VNZ/TEZ/D-IVA Phase 3 studies in adolescents and adults with F508del/minimal function variant (F/MF) genotypes (SKYLINE 102) or F/F and other responsive genotypes (SKYLINE 103) and children aged 6-11 years across all responsive genotypes (RIDGELINE 105). For participants aged ≥14 years, CF Questionnaire-Revised-8 Dimensions (CFQ-R-8D) utility scores, a CF-specific, preference-based scoring algorithm based on CFQ-R data, were compared for VNZ/TEZ/D-IVA and ELX/TEZ/IVA treatment through Week 52. For children aged 6-11 years, absolute changes in CFQ-R non-respiratory domain (CFQ-R non-RD) scores from baseline, following an ELX/TEZ/IVA run-in period, were assessed through Week 24. RESULTS: CFQ-R-8D utility scores were higher in adolescents and adults given VNZ/TEZ/D-IVA compared to ELX/TEZ/IVA (pooled 0.017; nominal P = 0.01); participants with F/MF genotypes had larger changes (0.031; nominal P = 0.004) compared to non-F/MF genotypes (0.008; nominal P = 0.35). Children treated with VNZ/TEZ/D-IVA had improvements in 6 out of 7 CFQ-R non-RD scores, ranging from 3.7 [95 % CI: 1.0, 6.3] points in emotional functioning to 7.2 [95 % CI: 3.8, 10.5] points in social functioning. CONCLUSIONS: VNZ/TEZ/D-IVA was associated with higher HRQoL in adolescents and adults aged ≥14 years compared to ELX/TEZ/IVA, with largest changes in participants with F/MF genotypes, and in children aged 6-11 years compared to ELX/TEZ/IVA baseline. These results highlight potential HRQoL benefits from greater CFTR function restoration with VNZ/TEZ/D-IVA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisQuality of LifeBenzodioxolesIndolesPyrazolesHumansChildMaleFemaleAdolescentDrug CombinationsAdultCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsChloride Channel AgonistsQuinolonesGenotypeCyclopropanesYoung AdultPyrrolidines

Stichwörter der Autor:innen

CFTR functionCystic fibrosisHealth-related quality of lifeVanzacaftor

Substanzen

BenzodioxolesIndolestezacaftorDrug CombinationsCystic Fibrosis Transmembrane Conductance RegulatorAminophenolsChloride Channel AgonistsQuinolonesPyrazolesCyclopropanes

Autor:innen und Institutionen

  • Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia. Electronic address: Wainwright@health.qld.gov.au.
  • Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Centre for Heart Lung Innovation, St. Paul's Hospital, and Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Department of Respiratory Medicine, Cardiff and Vale University Health Board, NHS Wales, Cardiff, UK.

Förderung

  • Vertex Pharmaceuticals Incorporated

Zitieren

APA

Wainwright, C. E., Thorat, T., Conner, S., Quon, B. S., Duckers, J., Lou, Y., Mo, C., Xue, Y., Zhu, L., & McGarry, L. (2026). Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.11.014

Vancouver

Wainwright CE, Thorat T, Conner S, Quon BS, Duckers J, Lou Y, et al. Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor. Journal of Cystic Fibrosis. 2026. doi:10.1016/j.jcf.2025.11.014

BibTeX
@article{Wainwright2026,
  author = {Wainwright, Claire E and Thorat, Teja and Conner, Sarah and Quon, Bradley S and Duckers, Jamie and Lou, Yiyue and Mo, Chen and Xue, Yuqing and Zhu, Ling and McGarry, Lisa},
  title = {Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor},
  journal = {Journal of Cystic Fibrosis},
  year = {2026},
  doi = {10.1016/j.jcf.2025.11.014}
}
Kostenlos starten →